Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 plus Osimertinib in First-Line EGFR+ NSCLC
NCT06735391Phase 3Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Oct 2024; status: recruiting.
02
Drugs
becotatug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06735391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735391.